1887

Abstract

SUMMARY

Infectivity titration, sedimentation analysis in sucrose gradients and electron microscopy have been used to study virus maturation following the reversal of the inhibition of vaccinia virus growth by rifampicin.

Electron-dense inclusions containing tubular structures develop in the cytoplasm of infected BHK 21/C 13 cells maintained in rifampicin, but the formation of immature and mature virus particles is prevented. The removal of rifampicin is followed by a rise of the virus infectivity. Spicule-covered membranes appear at the periphery of the inclusions and both immature and mature virus particles are seen. A proportion of the DNA synthesized in the presence of rifampicin is incorporated into particles and becomes resistant to deoxyribonuclease I. If protein synthesis is inhibited, spicule-covered membranes and immature particles appear but no mature particles are seen; the virus infectivity does not increase and the DNA remains susceptible to deoxyribonuclease I. It is suggested that rifampicin binds reversibly to a virus-specified protein, thereby preventing the formation of immature virus particles. Possible effects of rifampicin on the subsequent stages of virus maturation are discussed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-9-3-225
1970-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/9/3/JV0090030225.html?itemId=/content/journal/jgv/10.1099/0022-1317-9-3-225&mimeType=html&fmt=ahah

References

  1. Ben-Ishai Z., Heller E., Goldblum N., Becker Y. 1969; Rifampicin poxvirus and trachoma agent. Nature, London 224:29
    [Google Scholar]
  2. Cairns J. 1960; The initiation of vaccinia infection. Virology 11:603
    [Google Scholar]
  3. Dales S., Mosbach E. H. 1968; Vaccinia as a model for membrane biogenesis. Virology 35:564
    [Google Scholar]
  4. Goldman R. D., Follett E. A. C. 1969; The structure of the major cell processes of isolated BHK21 fibroblasts. Experimental Cell Research 57:263
    [Google Scholar]
  5. Heller E., Argaman M., Levy H., Goldblum N. 1969; Selective inhibition of vaccinia virus by the antibiotic rifampicin. Nature, London 222:273
    [Google Scholar]
  6. Joklik W. 1962; The purification of four strains of poxvirus. Virology 18:2
    [Google Scholar]
  7. Joklik W., Becker Y. 1964; The replication and coating of vaccinia DNA. Journal of Molecular Biology 10:452
    [Google Scholar]
  8. Mcauslan B. R. 1969; Rifampicin inhibition of vaccinia replication. Biochemical and Biophysical Research Communications 37:289
    [Google Scholar]
  9. Moss B., Katz E., Rosenblum E. N. 1969a; Vaccinia virus directed RNA and protein synthesis in the presence of rifampicin. Biochemical and Biophysical Research Communications 36:858
    [Google Scholar]
  10. Moss B., Rosenblum E. N., Katz E., Grimley P. M. 1969b; Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature, London 224:1280
    [Google Scholar]
  11. Sippel A., Hartmann G. 1968; Mode of action of rifamycins on the RNA polymerase reaction. Biochimica et hiophysica acta 177:218
    [Google Scholar]
  12. Subak-Sharpe J. H., Timbury M. C., Williams J. F. 1969; Rifampicin inhibits the growth of some mammalian viruses. Nature, London 222:341
    [Google Scholar]
  13. Subak-Sharpe J. H., Pennington T. H., Szilagyi J. F., Timbury M. C., Williams J. F. 1970; The effect of rifampicin on mammalian viruses and cells. First International Lepetit Colloquium p 260 Ed. by Silvestri L. Amsterdam: North-Holland Publishing Company;
    [Google Scholar]
  14. Wehrli W., Knusel F., Schmid K., Staehelin M. 1968; Interaction of rifamycin with bacterial RNA polymerase. Proceedings of the National Academy of Sciences of the United States of America 61:667
    [Google Scholar]
  15. Westwood J. C. N., Harris W. J., Zwartouw H. T., Titmuss D. H. J., Appleyard G. 1964; Studies On the structure of vaccinia virus. Journal of General Microbiology 34:67
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-9-3-225
Loading
/content/journal/jgv/10.1099/0022-1317-9-3-225
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error